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Background: NRP/B, a family member of the BTB/Kelch repeat proteins, is implicated in neuronal and cancer development, as well as 
the regulation of oxidative stress responses in breast and brain cancer. Our previous studies indicate that the NRP/B-BTB/POZ domain 
is involved in the dimerization of NRP/B and in a complex formation with the tumor suppressor, retinoblastoma protein. Although much 
evidence supports the potential role of NRP/B as a tumor suppressor, the molecular mechanisms of NRP/B action on E2F transcription 
factors have not been elucidated.
Methods: Three-dimensional modeling of NRP/B was used to generate point mutations in the BTB/Kelch domains. Tet-on inducible NRP/B 
expression was established. The NRP/B deficient breast cancer cell line, MDA-MB-231, was generated using lentiviral shNRP/B to evaluate 
the effect of NRP/B on cell proliferation, invasion and migration. Immunoprecipitation was performed to verify the interaction of NRP/B 
with E2F and histone deacetylase (HDAC-1), and the expression level of NRP/B protein was analyzed by Western blot analysis.Changes 
in cell cycle were determined by flow cytometry. Transcriptional activities of E2F transcription factors were measured by chloramphenicol 
acetyltransferase (CAT) activity.
Results: Ectopic overexpression of NRP/B demonstrated that the NRP/B-BTB/POZ domain plays a critical role in E2F-mediated transcriptional 
activity. Point mutations within the BTB/POZ domain restored E2-promoter activity inhibited by NRP/B. Loss of NRP/B enhanced the 
proliferation and migration of breast cancer cells. Endogenous NRP/B interacted with E2F and HDAC1. Treatement with an HDAC inhibitor, 
trichostatin A (TSA), abolished the NRP/B-mediated suppression of E2-promoter activity. Gain or loss of NRP/B in HeLa cells confirmed 
the transcriptional repressive capability of NRP/B on the E2F target genes, Cyclin E and HsORC (Homo sapiens Origin Recognition Complex). 
Conclusions: The present study shows that NRP/B acts as a transcriptional repressor by interacting with the co-repressors, HDAC1, providing 
new insight into the molecular mechanisms of NRP/B on tumor suppression.
(J Cancer Prev 2014;19:187-198)
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INTRODUCTION
Nuclear organization represents the dynamic networks and 
three-dimensional architectures of chromosomes and their 
regulatory components. The nuclear matrix and its associated 
proteins mediate the process of chromosome organization 
through the folding and looping of chromatin. Recent studies 
have demonstrated the role of nuclear matrix proteins in RNA 
processing, stress responses, cell adhesion, survival and tran-
scriptional regulation as either activators or repressors.
1-8 The 
nuclear matrix provides the foundation on which transcription 
factors operate.
9 Indeed, transcription factors, including tumor 
suppressors such as p53 and pRb are dynamically associated with 
specific nuclear matrix sites which support their functional 
complex formations.
10-14 Although aberrant expression or genetic 
mutation of nuclear matrix proteins have been found in many 188 Journal of Cancer Prevention Vol. 19, No. 3, 2014
cancers,
15-19 very little is known regarding the molecular mecha-
nism by which nuclear matrix proteins are involved in tumo-
rigenesis. 
We have previously characterized a nuclear matrix protein, 
NRP/B, also termed ENC1,
20,21 which is highly expressed in 
insoluble nuclear fractions and contains two major structural 
elements: a BTB/POZ domain and 115-amino acid motif in the 
predicted N-terminus and “Kelch” repeats consisting of about 50 
amino acids in the predicted C-terminal domain. NRP/B has been 
implicated in neuronal differentiation,
20,22 and malignant 
transformation, including glioblastoma, astrocytoma,
16,23,24 and 
colorectal cancer.
25,26 Mutations in NRP/B contribute to brain and 
colorectal tumorigenesis by promoting cell proliferation and 
decreasing cellular apoptosis.
16,25 In addition, NRP/B has been 
found to be involved in oxidative stress responses, both in 
human breast cancer and primary brain tumors.
3,4 The combi-
nation of sequence homology analysis and a three-dimensional 
model indicates several potential protein-protein interaction 
sites for NRP/B, via the BTB/POZ domain. Targeted mutagenesis 
studies have demonstrated that the N-terminus of the BTB/POZ 
domain of NRP/B is important for its dimerization.
22
The BTB/POZ domain is found primarily in zinc finger- 
containing transcription factors and mediates both homo- and 
hetero-dimerization in vitro.
22,27-29 The BTB/POZ family is im-
plicated in transcriptional repression, tumorigenesis, cell proli-
feration, and maintenance of embryonic stem cell pluripo-
tency.
30-33 A new mammalian BTB/POZ domain protein, DP- 
interacting protein, interacts with the DP component of the E2F 
heterodimer and is physically located as speckles in the nuclear 
envelope region.
34 In Drosophila melanogaster, transcription 
factors containing the BTB/POZ domain play a key role in a variety 
of developmental events such as photoreceptor development, 
muscle recognition by nerve cells and limb development.
35 A new 
human BTB/POZ domain protein, Fanconi Anemia Zinc Finger 
(FAZF), is homologous to the promyelocyte zinc finger protein 
(PLZF), which represses the transcription of specific targets by 
recruiting histone deacetylase (HDAC) through the SMART- 
mSin3-HDAC co-repressor complex. Both FAZF and PLZF are 
localized in nuclear speckles. FAZF is also a transcriptional 
repressor that is able to bind to the same DNA target sequence as 
PLZF
36 and forms a heterodimer with PLZF.  
The transcription factor E2F, a key element in the control of cell 
proliferation, regulates several families of genes whose products 
are required for cell cycle progression, such as cyclin E,
37 or for 
DNA synthesis,
38 such as dihydrofolate reductase.
39 E2F, in turn, 
plays an essential role in the G1-S transition.
40 pRb and other 
pocket binding proteins suppress E2F-mediated transcription in 
cells when they progress through the early G1 phase.
41,42 Further-
more, the pRb-E2F repressive complex functions in association 
with HDAC.
43-48 HDACs essentially repress transcription, pro-
bably through the deacetylation of histone tails.
49 Ferreira et al. 
(2001) reported that HDAC-1 is stably bound to an E2F target 
promoter during the early G1 phase in proliferating cells and is 
released at the G1-S transition, where pRb is known to be a 
transcriptional co-repressor, playing a key role in regulating cell 
proliferation and differentiation.
50  
In this study, we examined the role of NRP/B as a growth 
suppressor through the inhibition of human papillomaviral 
protein E2 promotor activity.
51 Immunoprecipitation analysis 
indicated that the association of NRP/B with E2F and HDAC-1 
were cell cycle dependant. Furthermore, NRP/B suppression of E2 
promoter activity was mediated through the BTB/POZ domain but 
not through "Kelch" repeats of NRP/B. The suppressive activity of 
NRP/B on E2F transcription was relieved by amino acid mutations 
(F45A, T46A, D47A, H60A, R61D, L64A) within the BTB/POZ 
domain. Moreover, treatment with the HDAC inhibitor, tricho-
statin A (TSA) restored the E2 promoter activity initially inhibited 
by NRP/B. Thus, NRP/B-mediated growth suppression appears to 
be directly related to the inhibition of E2F-mediated transcrip-
tion through the recruitment of a corepressor complex, including 
HDAC-1.
MATERIALS AND METHODS
1. Materials
The generation of monoclonal antibodies, VD2, against NRP/B 
was described.
20 The mouse ascites fluid containing monoclonal 
antibodies was further purified on a protein G-Sepharose co-
lumn. The purified antibodies were quantified using extinction 
coefficient 1.46 for 1 mg/mL antibody solution. Monoclonal 
anti-ENC1/NRP/B and pRb antibodies were purchased from BD 
Bioscience (San Jose, CA, USA). Antibodies, E2F1 and HDAC1 were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).  
2. Cell culture
PC-12, Neuro2A, HEK 293, HeLa, and MDA-MB-231 cell lines 
were obtained from American Type Culture Collection (Rockville, 
MD, USA). HEK 293, HeLa, Neuro2A, MDA-MB-231 cells were 
grown in DMEM medium, supplemented with 10% fetal bovine 
serum (FBS) (Invitrogen, Carlsbad, CA, USA) and penicillin/ 
streptomycin (Invitrogen). PC-12 cells were grown in RPMI 
medium supplemented with 10% horse serum and 5% FBS. We  
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previously generated PC-12 Tet-on/off cell lines stably expressing 
NRP/B.
22 The Tet-on/off PC12 clones were maintained as 
described.
3. Three-dimensional modeling of NRP/B
Both BLAST and AlignMaster programs used the PLZF BTB/POZ 
domain as a three-dimensional template. The structure of the 
human PLZF BTB/POZ domain was obtained from the Protein 
Data Bank (Protein Data Bank code 1BUO and 1CS3A). Superim-
position, model building, construction of insertion regions, 
structure validation and calculation of structural properties was 
carried out using subprograms ProMod v3.5, SPDBV v3.5, Loop 
v2.60, LoopDB v2.60, Parameters v3.5 and Topologies v3.5 which 
are available in the Automated SwissModel Package Program 
(www.expasy.ch/swissmod). The three- dimensional model of the 
NRP/B Kelch domain was generated from residue ranges between 
amino acids 292 through 575 of the conserved region in the Kelch 
domain, based on template 1zgkA by the use of BLAST2 and Cn3D 
program (www.ncbi.nlm.nih.gov, National Institute of Health). 
4. Construction of NRP/B expression vectors
NRP/B-GFP constructs were generated by standard methods. 
Briefly, full-length NRP/B cDNA was subcloned into the BamHI 
and HindIII sites of the pEGFP-N2 vector (Clontech, Palo Alto, CA, 
USA) by polymerase chain reaction (PCR) to generate 3'-end GFP 
ligated to NRP/B cDNA. The pNRP/B-delC2-GFP construct enco-
ding amino acids 296-589 was fused with GFP and was generated 
by PCR using NRP/B-specific oligonucleotides containing a 
restriction site linker and then subcloned into the BamHI and 
HindIII sites. pE2-chloramphenicol acetyltransferase (CAT) con-
structs were obtained from Dr. Mary R. Loeken (Josulin Diebetic 
Center, Boston, MA, USA). pCAG NRP/B was constructed by 
insertion of full-length NRP/B into EcoR1 and Not1 sites of pCAG 
obtained from Dr. Suzanne Topalian (National Cancer Institute, 
Bethesda, MD, USA). Generation of lentiviruses was performed as 
previously described.
52 Lentiviral shNRP/B (ENC1) expression 
vectors were purchased from Sigma (St. Louis, MO, USA). Cyclin E 
and HsOrC)-luciferase constructs were purchased from AddGene 
(Cambridge, MA, USA).
5. Immunoprecipitation and western blot analysis
Immunoprecipitation and Western blot analysis were perfor-
med as previously described.
20 
6. Flow cytometry analysis
Cells were transiently transfected with NRP/B-GFP wild-type 
(wt) using lipofectamine 2000 (Invitrogen) as described in the 
manufacturer's manual. Cells were harvested 48 h after tran-
sfection. Cell cycle analysis was performed as previously des-
cribed.
20 
7. Chloramphenicol acetyltransferase assay and lu-
ciferase reporter assay
CAT assays were performed as previously described.
53 Nuclear 
extracts were assayed in a volume of 150 L. All enzyme activities 
were assayed within the linear range. Percent conversion was 
determined by liquid scintillation quantitation of 
14C counts/min 
in acetylated and nonacetylated chloramphenicol spots from the 
chromatography plate. For the luciferase reporter assay, HeLa 
cells were split at 5 × 10
4 cells into 12-well plates and 
co-transfected with luciferase reporter constructs and target 
genes, such as E2F or NRP/B, alone with 5 ng of RL-CMV using 
Effectene Transfection reagent according to the manufacturer’s 
instructions (Qiagen, Gaithersburg, MD, USA). Whenever one of 
the DNA components was eliminated, the total amounts of DNA 
were balanced with a pcDNA3 empty vector. All transfections 
were performed in triplicates. After 24 hours, cells were lysed in 
passive lysis buffer and 20 l were used to measure the activity of 
E2 and Renilla  luciferase with dual luciferase reporter assay 
system (Promega, Milwaukee, WI, USA).    
8. Quantitative RT-PCR
Total RNA was purified using Trizol Reagent (Invitrogen) and 1 
g of total RNA was reverse transcribed in a 50 l reaction using 
TaqMan Reverse Transcription reagents (Applied Biosystems, 
Carlsbad, CA, USA). 2 l of the reverse transcribed cDNA was 
subjected to PCR according to Applied Biosystems technical 
recommendations. TaqMan probes for CyclinE and HsOrC were 
purchased from assay-on-Demand (Applied Biosystems). PCR 
primers for NRP/B were forward 5’-CAGTGGTGGCCTGAAA-
GAGA-3’ and reverse 5’-TGCAGACAGTAAGGCTGGCACT-3’. Tripli-
cate reactions were run for each RNA sample.
9. Wound healing migration assay
Wound healing migration assay was performed using a 35 
mm -Dish (ibidi GmbH, Munich, Germany). 70 l of DMEM 
containing 35,000 cells was seeded into each chamber of the cell 
culture insert. After 24 hours, the cell culture insert was gently 
removed with sterile tweezers, and 1 ml of fresh medium was 
added to the 35 mm -Dish. The cell migration toward the gap 
region was observed under an inverted light microscope 
(Olympus IX51, Olympus America lnc., Melville, NY, USA), and 190 Journal of Cancer Prevention Vol. 19, No. 3, 2014
Figure 1. Generation of NRP/B BTB and Kelch mutants based on three-dimensional modeling. (A) Schematic presentation of NRP/B protein 
and deletion mutants. IVS, intervening sequence. Numbers indicate amino acid residues. (B) Three-dimensional modeling and mutation in 
the BTB and Kelch domains. BTB mutants are as follows; mutant 1(mt1): Asp (D) 47 to Ala (A), Thr (T) 46 to Ala (A) and Phe (F) 45 to 
Ala (A); BTB mt2: His (H) 60 to Ala (A), Arg (R) 61 to Asp (D) and Leu (L) 64 to Ala (A); BTB mt3: mutations in mt1+ mt2. Red colors 
indicate a-helices and yellow colors indicate b-sheet structures. Mutation sites are shown as white balls. The Kelch domain of IZAGK  was 
used as a template. The NRP/B Kelch mutant includes Try (W) 518 to Ala (A). Thick arrows with green, yellow, blue, red, sky blue and orange 
colors indicate b-sheet of the Kelch repeat domain. Mutation sites are shown as sky-blue spheres. ΔC2, C-terminal deletion mutant; ΔN2, 
N-terminal deletion mutant. 
the images of each -Dish were taken after 0, 3, 5, 9, and 24 
hours.
 10. MTT assay
Cell viability was assessed by MTT assay. MDA-MB-231 cells 
were seeded at a concentration of 1×10
4 cells/ml in 96-well 
plates. The cells were incubated for 48 hours in medium 
supplemented with 10% FBS before the experiments. MTT 
solution (5 mg/ml) was added to each well after 24, 48, and 72 
hours and incubated at 37
oC to allow the formation of formazan 
crystal. After 2 hours, the media was carefully aspirated from the 
wells, and 200 l of DMSO (dimethyl sulfoxide) was added to 
dissolve the crystals. The absorbance at 570 nm was measured by 
spectrophotometry. All MTT assays were performed in quadru-
plicate.
11. Chamber cell-migration assay
8.0 m pore size PET (polyethylene terephthalate) track- 
etched membrane with Falcon cell culture insert (Becton 
Dickinson, Bedford, MA, USA) was used for chamber cell 
migration assay. A total number of 5 × 10
4 cells (500 ul) were 
added to the upper chamber, and 700 ul of fresh medium was 
added to the lower chamber. The chambers were incubated for 
24 hours at 37
oC, and the remaining cells on the upper surface  
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Figure 2. NRP/B regulated cell proliferation and migration. (A) Mouse neuroblastoma Neuro2A cells transfected with vectors expressing pEGFP
and NRP/B-GFP, were sorted out separately from the non-transfected population. Control cells were non-trasnfected cells. The parameters are 
averages of triplicate samples. (B) NRP/B Tet-off PC12 clones (SC10, SC11, SC13) were grown in the presence or absence of tetracycline for 
24 hours supplemented with 10% Tet system approved FBS (Clontech, Palo Alto, CA, USA). Cells were then analyzed by Flow cytomery as 
indicated in “Experimental procedures”. The results are mean values of triplicate samples from NRP/B PC12 clones. P-values were obtained 
by paired t-tests as shown. (C) Expression of NRP/B in MDA-MB-231 cells infected with lentiviral shNRP/B. (D) Loss of NRP/B enhanced cell 
proliferation. Cell viability was measured in shNRP/B clones of MDA MB-231 cell by MTT assay after 24, 48, and 72 hours. shSC stands for 
shScramble Control. (E) Cell migration toward the gap area was photographed at 0 and 24 hours. Perpendicular lines indicate the borders 
between gaps, and horizontal lines represent the width of gaps. The percentage of cell migration was calculated as follows: (W-w)/W x 100%: 
Width of gap (W at T = 0 hour) and width (w at T = 24 hours). The quantitative results of wound healing migration assay are presented 
on the right panel. (F) Representative images of the chamber cell migration assay show the effect of NRP/B on cell migration after toluidine 
blue staining of migrated cells. For quantification, cells were counted in three randomly determined fields. The data on the graph are the 
average number of migrated cells in the indicated cell lines.
of the membrane were removed with cotton swabs and gently 
washed with 500 ul of PBS. Cells that migrated through the 
membrane and attached to the lower surface of the membrane 
were fixed and stained with 70% ethanol and 1% toluidine 
blue solution. Stained cells were counted under microscopic 
observation to measure the average number of cells that had 
migrated.  
RESULTS
1. Three-dimensional modeling of NRP/B and the 
generation of point mutations in NRP/B domains
NRP/B contains both an -helical BTB/POZ domain and a - 
sheet Kelch repeats structure (Fig. 1A). We designed several 
mutants based on previously generated three-dimensional 
models of the NRP/B BTB/POZ domain (amino acid residues 
13-146)
22 and six Kelch repeat domains (amino acid residues 
294-533). For the modeling of the Kelch domain, we used a crystal 192 Journal of Cancer Prevention Vol. 19, No. 3, 2014
structure of ZGK Kelch as a template.
54 Loops were generated 
between Pro376-Ala380, Leu389-Leu393 and Ala401-Ser411 
within NRP/B Kelch repeats domain. The final total energy was 
–2339.067 KJ/mol. The calculated high energy level indicated that 
the Kelch domain needs to be stabilized by binding partners such 
as actin and suggests a possible critical site for actin binding in the 
Kelch domain of NRP/B. The final three-dimensional models of 
NRP/B and its mutants are shown in Figure 1B. The sites for point 
mutations are as follows; BTB mutant (mt) 1 (F45A, T46A, D47A), 
BTB mt2 (H60A, R61D, L64A), BTB mt3 (F45A, T46A, D47A, H60A, 
R61D, L64A) and Kelch mt1 (W518A). All the mutants contained at 
least one conserved residue of either BTB/POZ or "Kelch" repeats. 
The three-dimensional analysis of the NRP/B BTB/POZ domain 
indicated a potential pocket-formed structure that can be used as 
protein-protein interaction sites. Therefore, mutations in the 
BTB domain may change the ability of NRP/B to interact with 
other proteins via this domain. Moreover, this pocket site con-
tains highly conserved amino acids, indicative of its evolutionary 
conserved function. 
The “Kelch” model shows critical sites for actin binding. W518 
is located outside of the superbarrel structure to maintain the 
three-dimensional structure of the Kelch domain. W518 is also a 
highly conserved amino acid in the Kelch superfamily, and its 
charges, location and solvent accessibility strongly suggests its 
significance in the actin binding properties of the Kelch domain. 
2. The NRP/B played an important role in the regu-
lation of cell proliferation and migration
 Our previous studies demonstrated that NRP/B is involved in 
neuronal differentiation and proliferation.
20,22 However, the 
molecular mechanisms of NRP/B involvement in these cellular 
functions have not been elucidated yet. To examine the effect of 
NRP/B on cell proliferation, GFP-tagged full-length NRP/B wt was 
transfected into mouse neuroblastoma Neuro2A cells (Fig. 2A). 
GFP positive cells were sorted and analyzed for cell cycle profiles. 
FACS analysis showed that cells transfected with NRP/B wt were 
increased by 18-22% in the G0/G1 phase cell population (P = 
0.001) and decreased by 10-15% in the S phase cell population in 
comparison to the control and GFP-transfected cells. We further 
examined the growth suppressive effect of NRP/B using Tet-on/ 
off PC12 clones. Induction of NRP/B in the absence (Tet-off) or 
presence (Tet-on, data not shown) of tetracycline or doxycycline 
significantly (P  = 0.002) enhanced the G1/G0 population by 
15-20%, depending on the Tet-off PC12 clones used (Fig. 2B). 
Similar data was obtained from Tet-on PC12 clones (data not 
shown). Furthermore, to examine the loss of NRP/B function on 
cell proliferation and migration, shNRP/B MDA MB-231 cell lines 
were generated using lentiviral shNRP/B expression vector. 
Expression of NRP/B was confirmed by RT-PCR (Fig. 2C). The cell 
viability rates of the shNRP/B clone #2 and #5 were gradually 
increased depending on the incubation period for up to three 
days compared to the control shSC cells (Fig. 2D). Wound healing 
migration assay and chamber cell-migration assay proves that the 
loss of NRP/B amplified the migratory properties of MDA-MB-231 
cell lines, suggesting that the NRP/B deficiency in MDA-MB-231 
breast cancer cell line promotes advanced cell proliferation and 
tumorigenesis (Fig. 2E and 2F). 
3. Endogenous interaction of NRP/B with E2F tran-
scription factors and HDAC-1
The BTB domain of NRP/B specifically interacts with the TR 
subdomain within the B pocket of pRb and overexpresssion of 
NRP/B induces hyper-phospholylation of pRb.
22 Tumor suppres-
sive effects of pRb are known to mediate the inhibition of E2F 
transcriptional activity via its complex formation with E2F and 
HDACs during cell cycle progression.
41-44,55 To analyze if the cell 
cycle inhibitory effect of NRP/B is mediated through pRb-HADC 
transcriptional repressor complexes, we examined the endo-
genous interaction of NRP/B with transcription factor E2F and the 
transcriptional suppressor HDAC-1 in both quiescent and 
proliferating cells. Growth arrested HeLa cells via serum depri-
vation was stimulated with 10% serum for 12 hours and 24 hours 
where cells move from G1 to S phase respectively (Fig. 3A). Immu-
noprecipitation of NRP/B showed that endogenous NRP/B 
interacted with E2F and HDAC1 at late G1/S after 12 hours of 
serum stimulation. As cells entered S phase, HDAC1 was disso-
ciated from NRP/B-E2F complex (Fig. 3B). Co-transfection of 
NRP/B with other HDACs demonstrated that NRP/B also inte-
racted with HDAC2 and 5 (data not shown). Hence, the interac-
tion between NRP/B with E2F and/or HDAC-1 provides new 
partners for NRP/B in transcriptional regulation.
4. NRP/B inhibited E2F-mediated transcriptional acti-
vity
 To examine the effect of NRP/B on E2F-mediated gene tran-
scription, E2 promoter/enhancers were used (Fig. 3C). E2-CAT wt 
and deletion mutant constructs were co-transfected with 
plasmids expressing NRP/B into HeLa cells. NRP/B suppressed wt 
E2 and E2-80/70 promoter activity by 20-25%, and E2-80/70/  
–45/36 promoter activities by -30%. There was no significant 
change in E2-64/60, –45/36 (Fig. 3D and 3E). The effect of NRP/B 
on these E2 mutant CAT activities indicated that NRP/B  
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Figure 3. NRP/B inhibits E2-promoter activity. (A) Immunoassociation of NRP/B with transcription factor E2F and with HDAC-1. Growth-arrested
HeLa cells via serum deprivation (T = 0 hour) were stimulated with 10% fetal bovine serum for 12 and 24 hours. Total cell extracts (500 
g) were subjected to immunoprecipitation with monoclonal anti-NRP/B antibody and mouse IgG. Blot was probed with anti-E2F antibody 
and reprobed with anti-HDAC1 antibody. (B) Flow cytometry analysis. Cells in the same condition as above (A) were subjected to cell cycle 
analysis as described in “Experimental procedures”. Graph in the bottom panel indicates the quantification of the cell cycle profile. (C) 
Schematic diagram of the E2 promoter/enhancer. The position of the ATF binding site (from –82 to -66) is indicated by an empty box over 
the wild-type (wt) sequence. (D) Inhibition of specific E2 promoter activity by NRP/B in CAT assay. HeLa cells were co-transfected with E2-CAT
wt or E2-CAT mutant constructs in the presence or absence of NRP/B, together with a -galactosidase expression vector. p3M-E2, which contains
EIIA promoter sequences (–30 to +40), was used as a control. Extracts were prepared 48 hours after transfection and assayed for CAT activity 
as well as -galactosidase activity. (E) CAT activity is expressed as a percentage conversion of acetylated chloramphenicol, normalized to -gal-
actosidase activity in the above samples. IB, Immunoblot; IP, Immunoprecipitation; p3ME2, control vector; TATA, TATA box. 
specifically inhibited E2 promoter sites, but does not affect ATF 
sites (Fig. 3C-3E). To identify the specific inhibitory site, pre-
viously described NRP/B deletion and BTB point mutation con-
structs were co-transfected with the E2-CAT construct. E2 pro-
moter activity was inhibited by 65-78% with NRP/B wt and delC2 
mutant (Fig. 4A and 4B). However, NRP/B delN2 consisting of the 
Kelch motif did not show any significant effect on E2 promoter 
activity. Co-transfection of BTB mt 1 (F45A, T46A, D47A), mt 2 
(H60A, R61D, L64A) or mt 3 (F45A, T46A, D47A, H60A, R61D, 
L64A) with the E2-wt promoter construct showed that mutations 
in 45FTD47 and 60HR61D64 (BTB mt 3) dramatically abolished the 
suppression of E2F transcriptional activity, while mt 1 and 2 
showed partial inhibition (40-50%) (Fig. 4A and 4B). Therefore, E2 
promoter activity is mediated through the BTB domain of NRP/B, 
specifically within the regions of amino acids, 45FTD47 and 
60HR61L64.
Accumulating evidence indicates that pRb represses E2F tran-
scriptional activity by recruiting a HDAC.
43-48 HDACs act as 
transcriptional repressors by binding to E2F target promoters 
during the early G1 phase in proliferating cells.
50 Therefore, we 
investigated whether the transcriptional suppression of NRP/B is 
mediated through the recruitment of an HDAC repressor. To 
examine this, a specific inhibitor of HDAC-1, TSA, was used. E2F 
transcriptional activity inhibited by NRP/B (1 g) was restored in 194 Journal of Cancer Prevention Vol. 19, No. 3, 2014
Figure 4. Mutation in BTB domain and trichostatin-A (TSA) treatment restores E2-promoter activity suppressed by NRP/B. (A) E2 promoter 
activity was measured with extracts obtained from the transient transfection of NRP/B deletion mutants (C2 or N2) and expression  vectors 
containing point mutation in the NRP/B-BTB domain (NRP/B mt1, mt2 and mt3). NRP/B C2 contains the BTB/POZ domain whereas N2 contains 
only "Kelch" repeats. Control (Ctl) indicates the transfection of pE2-CAT wild-type alone. Cotransfection of E1A was used as a positive control. 
(B) Percent inhibition of E2-CAT activity was calculated by comparing CAT activities to the activity of the control (depicted as 0%), normalized 
to -galactosidase activity from the same samples of experiment. (C) Effect of TSA on NRP/B-mediated transcriptional repression of E2F tran-
scriptional activity. Cells were transfected with E2-CAT and/or NRP/B (1 g). Transfected cells were then treated with TSA (50, 100 and 200 
nM) for 24 hours. Extracts were prepared 48 hours after transfection. E2-CAT and -galactosidase activities were measured as described in 
“Experimental procedures”. (D) E2 promoter activity was measured following the transfection of pE2-CAT wt, E1A, or NRP/B expression vector
(1, 3, and 5 g), and a -galactosidase expression vector in the presence or absence of TSA (100 nM). Transfected cells were treated with 
TSA for 24 hours and extracts were subjected to CAT assay. Ctl, Control; ΔC2, C-terminal deletion mutant; ΔN2, N-terminal deletion mutant;
p3ME2, E2 control palsmid.
cells treated with TSA (50 nM), with an 80-95% increase in E2 
promoter activity (Fig. 4C and 4D). The inhibitory effect of NRP/B 
on E2 promoter activity showed concentration dependant pro-
perties. With an increase of NRP/B concentration, the E2 pro-
moter activity was significantly inhibited by 70-90% as compared 
to E2-CAT alone (Fig. 4D). TSA (100 nM) alone increased E2F 
promoter activity by 40% and recovered over 90% of the E2 
promoter activity inhibited by NRP/B. However, in the presence of 
high concentration of NRP/B (3-5 g), TSA treatment did not 
inhibit NRP/B-mediated suppression of E2 promoter activity (Fig. 
4D). Taken together, these results indicate that NRP/B served as a 
transcriptional repressor in E2 promoter activity by recruiting 
HDAC-1.
5. Regulation of E2F-target gene promoter activity 
and gene transcription via NRP/B
To determine whether the transcriptional suppressive activity 
of NRP/B correlates to regulation of E2F target genes, we first 
examined the effect of NRP/B on the promoters of Cyclin E and 
HsOrC. As shown previously in Figure 3 and 4, NRP/B inhibited 
E2F-mediated transcriptional activity. E2F enhanced the activity 
of two E2F target gene promoters, HsOrC and Cyclin E by 2 to 6 
folds, respectively (Fig. 5A and 5B). In addition, ectopic over-
expression of NRP/B in HeLa cells significantly inhibited basal 
and E2F-mediated Cyclin E and HsOrC transcriptional activities 
(Fig. 5A and 5B). Furthermore, we used the lentiviral-based NRP/B 
and shNRP/B to examine the gain and loss of NRP/B function on 
E2F target gene expression in HeLa cells. Expression of NRP/B was  
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Figure 5. NRP/B inhibits E2F-target gene promoters and gene transcription in H e L a  c e l l s .  ( A  a n d  B )  L u c i f e r a s e  a c t i v i t y  i n  H e L a  c e l l s  a f t e r 
transfection with Cyclin E (A) and HsOrC. (B) reporter constructs, along with E2F or NRP/B as indicated. pGL, an empty reporter vector was 
used as a control. The experiments were repeated with triplicate samples at least three times and the representative experiment is shown. 
(C and F) Expression of NRP/B protein in HeLa cells infected with increasing amount of lentiviral-pCAG-NRP/B (C) and lentiviral-shNRP/B (F). 
30  g of total cell lysates were subjected to western blot analysis. (D, E, G and H) qRT-PCR of Cyclin E (D and G) and HsOrC (E and H). 
Total mRNA was prepared from cells infected with lentiviral-pCAG-NRP/B and lentiviral-shNRP/B as shown in (C and F). Viral products from 
pCAG-GFP (D and E) and shGFP (G and H) were used as controls. The results are mean values of relative mRNA levels normalized to 18S 
± SEM from triplicate samples. P-values were obtained by paired t-tests as shown. Luc, luciferase.
gradually increased by lentiviral-NRP/B infection and markedly 
decreased by shNRP/B expression (Fig. 5C and 5F). qRT-PCR 
analysis showed that the ectopic expression of NRP/B signifi-
cantly suppressed cyclin E (P < 0.03) and HsOrC (P < 0.02) gene 
transcript (Fig. 5D and 5E). Loss of NRP/B by shNRP/B showed a 
significant increase of Cyclin E (P < 0.01) and HsOrC (P < 0.05) 
gene transcripts (Fig. 5G and 5H). These results further validate 
the role of NRP/B as a transcriptional suppressor in E2F-mediated 196 Journal of Cancer Prevention Vol. 19, No. 3, 2014
transcriptional activity. 
DISCUSSION
NRP/B is known to exert its effect on neuronal differentiation 
and proliferation through its association with the key molecules 
in cell cycle, such as pRb.
20 We have shown previously that the 
NRP/B-BTB/POZ domain mediated the association of NRP/B with 
pRb through the TR subdomain within the B pocket of the pRb 
protein.
22 Mutations in the BTB domain significantly reduced the 
NRP/B-pRb interaction and dimerization of NRP/B. The present 
study indicates that the NRP/B had significant growth inhibitory 
properties (Fig. 2A and 2B). After transfection of NRP/B-GFP into 
Neuro2A and HEK 293 cells, the population of G0/G1 was 
increased by 15-20% in comparison to non-transfected and mock 
(GFP only) transfected cells. The growth regulatory effect of 
NRP/B was also verified in several Tet-on/off PC12 clones (Fig. 2B). 
We found that the induction of NRP/B in Tet-on/off cell lines 
significantly delayed the kinetics of cell cycle progression in 
comparison to control cells (unpublished data). Interestingly, 
long-term (two to four days) ectopic overexpression of NRP/B in 
Tet-on/off PC12 clones induced the neuronal differentiation of 
PC12 in which pRb became hyper-phosphorylated.
22 On the other 
hand, the loss of NRP/B in MDA-MB-231 cells showed a marked 
increase in cell proliferation and migration, which validates the 
growth inhibitory function of NRP/B, suggesting that NRP/B may 
have tumor suppressive properties. Regulation of E2F-mediated 
transcription may lead to a better understanding of the molecular 
mechanisms of cellular progression. The activity of the E2F 
transcription factor in cells is tightly regulated, partly through 
complex formations with a number of key regulators of cellular 
proliferation and cell cycle control. Interaction of pRb with E2F in 
the G0/G1 phase is known to inhibit cell proliferation.
20,22,23 Since 
NRP/B interacts with E2F, HDAC1 and pRb depending on cell cycle 
progression, it is crucial to understand the molecular mechanism 
of NRP/B action on these growth regulatory proteins. Our studies 
showed that NRP/B suppressed E2 promoter activity, which was 
mediated by the BTB domain but not by the Kelch motif. Within 
the NRP/B-BTB domain, amino acids (45FTD47, and 60HR61L64) were 
important in regulating E2 promoter/E2F binding activities. 
Among these amino acids, 46TD47 are known to be conserved and 
essential for the transcriptional suppression of PLZF. Further-
more, the inhibition of HDAC1 activity via treatment of TSA 
restored E2F transcriptional activity initially suppressed by 
NRP/B, suggesting that the complex formation of NRP/B-E2F- 
HDAC1 in the late G1/S phase (Fig. 3A and 3B) may lead to 
transcriptional suppression. It is conceivable that the recruit-
ment of HDAC1 and/or the hypophosphorylated form of pRb
20 
could engage the E2F-transcriptinal machinery. Indeed, NRP/B 
seems to be involved in E2F transcriptional suppression, by 
interacting with HDAC1-E2F. Earlier studies have shown that the 
cell cycle-dependant recruitment of HDAC-1 is correlated with the 
deacetylation of histone H4 on a pRb-E2F target promoter.
50 The 
histone methylase SUV39H1 and the methylase-lysine binding 
protein HP1 are involved in the repressive functions of pRb.
56 
Thus, the pRb functions, at least partly, as a repressor through the 
recruitment of HDAC activity.
40,46,47 Regulation of the E2F- 
mediated transcriptional activity via NRP/B was further examined 
in both E2F target gene promoters (Cyclin E and HsOrC) and gene 
transcription, indicating that ectopic overexpression of NRP/B 
significantly inhibited not only the promoter activities but also 
the gene transcription of the E2F target genes, Cyclin E and HsOrC 
(Fig. 5). However, loss of NRP/B by infection of lentiviral shNRP/B 
enhanced E2F target gene transcription respectively. NRP/B could 
possibly impair the formation of E2F complex in order to 
interrupt the activation of E2F-mediated transcription. NRP/B 
could indirectly bind to E2F sites through the formation of a 
DNA-protein complex that contains E2F1, pRb and HDACs.  
Taken together, NRP/B acts as a transcriptional suppressor. 
Inhibition of E2F-mediated transcription through NRP/B interac-
tion with co-repressors may significantly impact cell proliferation 
and tumorigenesis. 
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